Latest News

22.7.25

Prognostic implications of splenomegaly in BCMA-directed CAR T-Cell therapy for relapsed myeloma

New CERTAINTY-supported publication identifies spleen size as a prognostic marker in CAR T cell treatment

8.7.25

A seamless transition of expertise ensures continued progress in stakeholder engagement and socio-economic research

3.7.25

New article highlights CERTAINTY’s approach to advancing personalised treatment

15.6.25

PET/CT helps identify high-risk myeloma patients after CAR T therapy

$Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma$

12.6.25

Registry study confirms cilta-cel’s superior outcomes in real-world multiple myeloma treatment